Cost-effectiveness of treatment with ACE inhibitors or beta blockers among eligible but untreated patients in terms of net health benefit (QALYs)
| Usual care | Addition of treatment | Incremental costs per patient | Incremental QALYs per patient | ICER (cost per QALY) | Incremental NHB in QALYs (threshold: £20 000 per QALY) per patient | Incremental NHB in QALYs (threshold: £13 000 per QALY) per patient |
| No treatment | ACEi | £14.50 | 0.1699 | Dominant | 0.1706 | 0.1710 |
| No treatment | BB | £44.57 | 0.4131 | £107.88 | 0.4109 | 0.4097 |
| No treatment | ACEi and BB | £66.10 | 0.5814 | £113.69 | 0.5781 | 0.5763 |
| AA | ACEi | £53.64 | 0.1686 | £318.11 | 0.1659 | 0.1645 |
| AA | BB | £110.79 | 0.4046 | £273.81 | 0.3991 | 0.3961 |
| AA | ACEi and BB | £198.50 | 0.5639 | £352.03 | 0.5539 | 0.5486 |
| ACEi | BB | £80.60 | 0.4116 | £195.84 | 0.4075 | 0.4054 |
| BB | ACEi | £21.53 | 0.1683 | £127.96 | 0.1672 | 0.1666 |
| AA and ACEi | BB | £144.86 | 0.3952 | £366.50 | 0.3880 | 0.3841 |
| AA and BB | ACEi | £87.70 | 0.1592 | £550.78 | 0.1548 | 0.1525 |
AA, aldosterone antagonist; ACEi, ACE inhibitor; BB, beta blocker; ICER, incremental cost-effectiveness ratio; NHB, net health benefit; QALY, quality-adjusted life-year.